GLP-1 Weight Loss and Muscle Function: Why I Look Beyond the Scale

Do GLP-1 medicines cause muscle loss?

Some lean mass can be lost during treatment, alongside fat. Lean mass includes muscle but also water and other non-fat tissues, so a change in that measurement does not tell the whole story about your muscles.[1,3]

A review published in the European Journal of Clinical Investigation found that weight loss with GLP-1 receptor agonists was predominantly fat loss, with no consistent deterioration in strength or physical function across the evidence reviewed.[1]

That does not mean every person has the same experience. One study followed older men with type 2 diabetes for a year and reported declines in strength and physical performance in the semaglutide group. It also measured blood markers associated with nerve and muscle health.[2] Those findings deserve attention, but they describe a particular population and do not establish what will happen to every person using a weight-loss medicine.

My takeaway is to avoid assumptions in either direction. A change on the scale does not tell me how you will respond during an assessment, and a weaker muscle test does not tell me what caused it.

Why muscle size is only part of the picture

What do you want to be able to do more comfortably or confidently?

That is a useful starting point for our conversation. You might want to walk with your family or feel more comfortable getting through a workday. The assessment needs to connect with something that matters in your life.

I ask what you notice and compare that with what I observe during the session. Your experience and my findings provide different information. Neither needs to be dismissed because the other looks encouraging.

If you have noticed a new or worsening difficulty, bring it to your prescribing clinician's attention rather than assuming that weight loss explains it. A CMAR session does not replace that evaluation.

What I assess at CMAR

I begin with an assessment of movement. This includes active range of motion, where you move yourself, and passive range of motion, where I move a joint while you relax. I also compare responses during muscle testing.[4]

When I describe a muscle as weaker in that setting, I mean that it responded less strongly during the tests I performed. That finding helps direct my work. It is not proof of damaged nerve-to-muscle connections, a medication effect or the cause of your symptoms.

Where my assessment indicates hands-on work, I reassess afterwards. I also ask what you notice: whether standing feels different, for example, or how walking compares with the beginning of the visit.

A change during a session is worth recording. It does not establish a lasting result or explain a particular nervous-system mechanism.

I describe this process in more detail in What Does Muscle Activation Mean at CMAR?

How I choose your Purposeful Motions

Your programme follows your assessment. I select Purposeful Motions connected to the muscles identified during that session, rather than hand you a standard list because you take a particular medicine.[4]

At later visits, I assess again. Your programme should reflect what I find then, including whether a motion can be removed. More is not automatically better; I want you to understand what you are practising and why.

This is my practice-based approach to individual care. I am not presenting Purposeful Motions as a proven way to prevent GLP-1-related muscle loss, preserve neuromuscular junctions or replace strength training recommended by your healthcare team. The research cited here does not test CMAR's methods.

Where exercise and nutrition fit

A joint advisory from nutrition, lifestyle-medicine and obesity organisations recommends attention to adequate nutrition and resistance training during GLP-1 treatment. It also explains that increasing protein alone is unlikely to preserve muscle adequately without appropriate strength training.[3]

What that looks like for you needs to fit your health and circumstances. Discuss your exercise plan with your healthcare team, and ask your prescribing clinician or a registered dietitian about nutrition needs. This article cannot set your protein target or clear you for exercise.

CMAR's individualised movement work should not be confused with a complete medical weight-management, nutrition or resistance-training programme.

What is worth bringing to a conversation?

Start with the activity that matters to you and what you have noticed. If something feels harder, describe when it happens and whether it seems to be changing. Include relevant guidance or restrictions from your healthcare team.

You do not need to arrive with an explanation for which muscle is involved. My assessment is where I begin exploring movement with you.

For a little more preparation, read what to bring to a muscle activation conversation. Ask how to share sensitive health information securely before sending it by ordinary email.

Should you change your medicine if you feel weaker?

Speak with your prescribing clinician. Do not stop or change a prescribed medicine on the basis of this article or a CMAR muscle test.

Within my own work, worsening findings call for reassessment, not a reason to push through. If repeat testing or your response to treatment worsens, I stop treatment and consider the appropriate next steps involving your physician.[4]

Care that starts with you

I want you to leave a session with a clearer understanding of what I assessed and how your programme relates to it. The aim is practical: supporting everyday function and helping you work towards greater confidence in your body, without promising an outcome in advance.

If you would like to discuss an individual assessment, explore in-person sessions with Brent. CMAR offers visits at homes and workplaces in the Denver area; travel farther afield is considered individually.

Start with what you want to be able to do. We can discuss whether CMAR's approach is an appropriate part of your care.